Cryoport, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

CYRX

10-K: Cryoport Reports Strong 2025 Revenue Growth, Strategic Divestiture

Cryoport, Inc. reported a 12.4% increase in total revenue to $176.2 million for fiscal year 2025, driven by strong demand in life sciences services and products, alongside the strategic divestiture of its CRYOPDP business.

NASDAQ

7 Mar 2025

CYRX

Cryoport, INC

10-K: Cryoport Reports Mixed Results for 2024, Navigating Market Challenges

Cryoport's 2024 results reveal a slight revenue decrease alongside strategic cost management and significant non-cash impairment charges.

NASDAQ

13 Mar 2024

CYRX

Cryoport, INC

10-K: Cryoport's 2023 10-K Filing: Strategic Acquisitions and Global Expansion Drive Growth Amidst Market Challenges

Cryoport's 2023 annual report highlights strategic acquisitions, global expansion, and a focus on cell and gene therapy supply chain solutions, while also addressing challenges such as decreased product revenue and a goodwill impairment.